Processa Pharmaceuticals, Inc. completed its acquisition of Vidya Therapeutics, Inc. on 2026-07-28, according to the Form 8-K Processa Pharmaceuticals, Inc. filed with the SEC on 2026-07-29. The filing states a price of $200 million.
| Acquirer | Processa Pharmaceuticals, Inc. |
|---|---|
| Acquired | Vidya Therapeutics, Inc. |
| Completed | 2026-07-28 |
| Price stated in the filing | $200 million |
| Reported by | Processa Pharmaceuticals, Inc. (PCSA), the buyer |
| Filing | Form 8-K, filed 2026-07-29 |
Want the whole picture on Processa Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Processa Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Processa Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On July 28, 2026, the Company completed its acquisition of Vidya pursuant to the Merger Agreement.
The price, in the filing's words
Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 163,774.679 shares of Series A Preferred Stock (the " PIPE Securities ") for an aggregate cash purchase price of approximately $200.0 million (collectively, the " Financing ").
More from the filing
- Completion of Acquisition or Disposition of Assets.
Agreement and Plan of Merger On July 28, 2026, Processa Pharmaceuticals, Inc., a Delaware corporation (the " Company " or " Processa "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), by and among the Company, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (" Merger Sub I "), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (" Merger Sub II "), and Vidya Therapeutics, Inc., a Delaware corporation (" Vidya ").
Also, on July 28, 2026, the transactions contemplated by the Merger Agreement were consummated, pursuant to which Merger Sub I merged with and into Vidya, with Vidya surviving and becoming a wholly owned subsidiary of the Company (the " First Merger ").
Quoted from Processa Pharmaceuticals, Inc.'s Form 8-K.
This is the only completed acquisition Processa Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Processa Pharmaceuticals, Inc.Look up Processa Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.